Open access
Sep 2026
Integration of proteomic aging clocks in a phase 2a clinical trial supports simultaneous geroprotective assessment.
This work supports the goal of dual-purpose clinical trial designs that integrate aging endpoints into studies for specific disease indications by identifying potential anti-aging shifts in senescence and metabolic processes alongside the anti-fibrotic activity of rentosertib.
Alex Zhavoronkov, F. Galkin, Shan Chen et al.
· Nature Biotechnology · 1 citation